Aradigm Corp. (ARDM) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aradigm Corp. (ARDM) Announces Approval of EMA Request to Review Pulmaquin
March 17, 2016 7:09 AM EDTAradigm Corporation (Nasdaq: ARDM) announced that the European Medicines Agency (EMA) has approved its request to review Pulmaquin, Aradigms investigational inhaled liposomal ciprofloxacin product, under the Centralised Authorisation Procedure drug review process. This procedure results in a single marketing authorization that is valid... More
